The Current Ratio as of December 2024 (TTM) for ImmunityBio, Inc. (IBRX) is 2.68

According to ImmunityBio, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 2.68. This represents a change of -29.90% compared to the average of 3.82 of the last 4 quarters.

ImmunityBio, Inc. (IBRX) Historical Current Ratio (quarterly & annually)

How has IBRX Current Ratio performed in the past?

The mean historical Current Ratio of ImmunityBio, Inc. over the last ten years is 11.17. The current 2.68 Current Ratio has changed 2.30% with respect to the historical average. Over the past ten years (40 quarters), IBRX's Current Ratio was at its highest in in the September 2015 quarter at 53.91. The Current Ratio was at its lowest in in the June 2023 quarter at 0.11.

ImmunityBio, Inc. (IBRX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of ImmunityBio, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

ImmunityBio, Inc. (IBRX) Average Current Ratio

How has IBRX Current Ratio performed in the past?

The current Current Ratio of ImmunityBio, Inc. (IBRX) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

ImmunityBio, Inc. (IBRX) Current Ratio vs. Peers

How is IBRX’s Current Ratio compared to its peers?

ImmunityBio, Inc.’s Current Ratio is less than BioLineRx Ltd. (0), greater than Ardelyx, Inc. (1.52), less than Lexicon Pharmaceuticals, Inc. (4.03), less than Seres Therapeutics, Inc. (7.45), greater than eFFECTOR Therapeutics, Inc. (1.12), greater than Protalix BioTherapeutics, Inc. (1.03), greater than PDS Biotechnology Corporation (1.98), less than aTyr Pharma, Inc. (2.84), less than Elevation Oncology, Inc. (6.07), less than CureVac N.V. (17.77), less than Reata Pharmaceuticals, Inc. (6.20), less than Krystal Biotech, Inc. (6.75), less than Vir Biotechnology, Inc. (7.97), less than Propanc Biopharma, Inc. (8.94), greater than Viking Therapeutics, Inc. (0.01), less than TG Therapeutics, Inc. (36.47), less than X4 Pharmaceuticals, Inc. (4.59), less than Madrigal Pharmaceuticals, Inc. (4.89), less than null (5.98),

Build a custom stock screener for ImmunityBio, Inc. (IBRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ImmunityBio, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

ImmunityBio, Inc. (IBRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like ImmunityBio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.